Role of Nod2 and AMP-kinase in obesity-associated liver cancer

Nod2 和 AMP 激酶在肥胖相关肝癌中的作用

• 批准号: 10512198
• 负责人: Dipika Gupta
• 金额: $ 7.93万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10512198
• 关键词: Address; Autophagocytosis; Bacteria; Binding; Bioinformatics; Body Weight; Cancer Etiology; Carcinogens; Cell Line; Cell Proliferation; Cell physiology; Cessation of life; Chronic; Clinical; Crohn' s disease; Data; Development; Diabetes Mellitus; Disease; Future; Gene Expression; Genes; Goals; Health; Hepatocarcinogenesis; High Fat Diet; Hyperglycemia; Hyperlipidemia; Incidence; Individual; Inflammation; Inflammatory; Innate Immune Response; Innate Immune System; Insulin Resistance; Liver; Liver neoplasms; Malignant Epithelial Cell; Malignant Neoplasms; Malignant neoplasm of liver; Metabolic; Metabolic Diseases; Metabolic dysfunction; Metabolism; Metformin; Methods; Mission; Mitochondria; Molecular; Monitor; Mus; Mutation; Natural Immunity; Obesity; Obesity associated liver disease; Pathway interactions; Pattern recognition receptor; Phosphotransferases; Predisposition; Prevention; Primary carcinoma of the liver cells; Principal Investigator; Process; Proteins; Public Health; Publishing; Regulation; Research; Risk Factors; Role; Role Concepts; STK11 gene; Testing; United States National Institutes of Health; adenylate kinase; base; biological adaptation to stress; cancer therapy; colitis associated cancer; diet-induced obesity; differential expression; dimethylbenzanthracene; experimental study; fatty liver disease; hepatocellular carcinoma cell line; in vivo; knock-down; lipid biosynthesis; liver cancer model; liver development; microbiota; mouse model; non-alcoholic fatty liver disease; obese person; obesity development; obesity prevention; obesity treatment; overexpression; programs; protein activation; pup; tumorigenesis; tumorigenic

Liver cancer is one of the fastest increasing causes of cancer-related deaths in the U.S. and worldwide. There are approximately 700,000 deaths worldwide each year due to liver cancer. Risk factors for liver cancer include nonalcoholic fatty liver disease, diabetes, and obesity, and the rising incidence in these diseases is paralleled with an increasing incidence in liver cancer. The development of hepatocellular carcinoma, the major subtype of liver cancer, is a multistep process and often starts with chronic inflammation. However, the molecular and cellular causes of inflammation remain poorly understood. Nod2 is a bacterial innate immunity protein and Nod2 deficiency is associated with inflammatory diseases, diet-induced obesity and metabolic dysfunction, and obesity-dependent liver cancer. Preliminary data, using a mouse model for hepatocellular carcinoma, predicts that the development of liver tumorigenesis in Nod2-deficient mice on high fat diet (HFD) is associated with an inhibition of the AMP- dependent kinase (AMPK) pathway. AMPK is a master regulator of metabolic reprogramming and cell proliferation. However, the role of the AMPK pathway in liver tumorigenesis in Nod2-deficient mice has not been demonstrated. In the current project, the hypothesis that there is decreased activation of the AMPK pathway in Nod2-/- tumorigenic mice, which contributes to the development of hepatic tumors in these mice will be tested. In Aim 1, the role of Nod2 in the activation of the AMPK pathway will be determined. WT and Nod2-/- mice will be treated with the carcinogen dimethylbenz[a]anthracene (DMBA) and maintained on HFD (DMBA+HFD) to induce liver tumors and regulation of proteins in the AMPK pathway will be determined in the liver. In Aim 2, the role of the AMPK pathway in the development of obesity-dependent hepatic tumors in Nod2-/- mice will be determined. Nod2-/- DMBA+HFD mice will be treated with metformin to activate AMPK and monitored for the development of hepatic tumors. The results from these experiments will provide proof-of-concept for the role of Nod2 in activation of the AMPK pathway and for the role of this pathway in protection from the development of hepatocellular carcinoma and will provide preliminary data for future in-depth studies to determine the molecular basis of obesity-dependent liver cancer.

在美国，肝癌是癌症相关死亡人数增长最快的原因之一 全世界。全球每年约有70万人死于肝癌。风险因素 包括非酒精性脂肪性肝病、糖尿病和肥胖症，以及 这些疾病与肝癌发病率的增加是平行的。肝细胞癌的研究进展 癌症是肝癌的主要亚型，是一个多步骤的过程，通常始于慢性 发炎。然而，炎症的分子和细胞原因仍然知之甚少。 NOD2是一种细菌天然免疫蛋白，NOD2缺乏与炎症有关 疾病，饮食引起的肥胖和代谢功能障碍，以及肥胖依赖型肝癌。初步 使用小鼠肝细胞癌模型的数据预测，肝脏的发育 高脂饮食(HFD)NOD2基因缺陷小鼠的肿瘤发生与抑制AMP-2有关 依赖激酶(AMPK)途径。AMPK是新陈代谢重新编程和细胞的主要调节器 扩散。然而，AMPK通路在NOD2缺陷小鼠肝脏肿瘤发生中的作用尚未见报道 已经被证明了。 在目前的项目中，假设在NOD2-/-中AMPK通路的激活减少 将对导致这些小鼠肝脏肿瘤发展的致瘤小鼠进行测试。在AIM 1，将确定NOD2在AMPK通路激活中的作用。WT和NOD2-/-小鼠将被 用致癌物二甲基苯并[a]菲(DMBA)处理，并在HFD(DMBA+HFD)上保持，以 诱导肝脏肿瘤和调节AMPK通路中的蛋白质将在肝脏中确定。在目标2中， AMPK通路在肥胖依赖的NOD2/-小鼠肝肿瘤发展中的作用将是 下定决心。NOD2-/-DMBA+HFD小鼠将被二甲双胍激活AMPK并监测 肝脏肿瘤的发展。这些实验的结果将为以下角色提供概念证明 NOD2在AMPK通路的激活中的作用以及该通路在防止肿瘤发生发展中的作用 并将为未来的深入研究提供初步数据，以确定 肥胖依赖型肝癌的分子基础。